Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $11.1 million.

  • Zevra Therapeutics' Accounts Payables fell 5474.17% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 5474.17%. This contributed to the annual value of $25.5 million for FY2024, which is 1037.57% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Accounts Payables is $11.1 million, which was down 5474.17% from $15.8 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Accounts Payables peaked at $28.4 million during Q4 2023, and registered a low of $2.1 million during Q3 2021.
  • In the last 5 years, Zevra Therapeutics' Accounts Payables had a median value of $10.5 million in 2023 and averaged $12.0 million.
  • Per our database at Business Quant, Zevra Therapeutics' Accounts Payables crashed by 5549.49% in 2021 and then surged by 36041.5% in 2023.
  • Zevra Therapeutics' Accounts Payables (Quarter) stood at $3.0 million in 2021, then surged by 103.06% to $6.2 million in 2022, then surged by 360.41% to $28.4 million in 2023, then dropped by 10.38% to $25.5 million in 2024, then plummeted by 56.51% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $15.8 million for Q2 2025, and $17.8 million during Q1 2025.